Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. In vitro pharmacological profile of TAK-931.
  • Fig. S2. Effect of TAK-931 on DNA replication, RS, and DDR.
  • Fig. S3. Irreversible antiproliferative effects of TAK-931 and mitotic aberrations.
  • Fig. S4. Large-scale in vitro cell panel studies of TAK-931.
  • Fig. S5. Effect of KRAS mutation on TAK-931 antiproliferative activity, showing unique antiproliferative spectrum in cancer cells.
  • Fig. S6. PK/PD/efficacy study of TAK-931 in tumor xenograft mouse model.
  • Fig. S7. Antitumor efficacy of TAK-931 in tumor xenograft mouse model.
  • Fig. S8. Pathway network between CDC7 and KRAS knockdown.
  • Table S1. Phosphorylation sites modulated after 4 and 24 hours of TAK-931 treatment in COLO205 cells.
  • Table S2. %T/C values of antitumor efficacy studies in colorectal, lung, ovarian, and pancreatic PDXs.

Download PDF

Files in this Data Supplement: